- ICH GCP
- US Clinical Trials Registry
- Klinisk forsøg NCT07696689
Evaluating the Optimal Timing of Trans-Anal Irrigation for Low Anterior Resection Syndrome Post-rectal Cancer Surgery (EARLY-TAI)
Evaluating the Optimal Timing of Trans-Anal Irrigation for Low Anterior Resection Syndrome Post-rectal Cancer Surgery - An Italian Multicentre Randomised Study
This study aims to evaluate the optimal timing of trans-anal irrigation (TAI) for participants with low anterior resection syndrome (LARS) who have undergone surgery for rectal cancer.
The main question it aims to answer is:
"Can starting TAI within three months of stoma closure reduce the number of daily bowel movements in people who have undergone rectal surgery?" Researchers will compare the outcomes for participants who start TAI within the first three months with those who start after three months, to see if early TAI can reduce the number of daily bowel movements more effectively than starting later.
The study will also determine whether early TAI can improve typical bowel symptoms, enhance quality of life, and increase satisfaction with treatment as much as when it is performed more than three months after stoma closure.
Participants will:
- Undergo a preliminary visit to assess their eligibility to participate
- Undergo training to understand how to use the device correctly
- Perform regular TAI
- Undergo four control visits at 1, 3, 6 and 9 months after the start of treatment.
Studieoversigt
Status
Betingelser
Intervention / Behandling
Undersøgelsestype
Tilmelding (Anslået)
Fase
- Ikke anvendelig
Kontakter og lokationer
Studiekontakt
- Navn: Simona Ascanelli Ascanelli, MD, Department of Surgery
- Telefonnummer: +39 348 6909238
- E-mail: simona.ascanelli@unife.it
Deltagelseskriterier
Berettigelseskriterier
Aldre berettiget til at studere
- Voksen
- Ældre voksen
Tager imod sunde frivillige
Beskrivelse
Inclusion Criteria:
- Adults aged ≥ 18 years
- Colorectal resection for rectal cancer with a protective ostomy
- Integrity of the colorectal or coloanal anastomosis, as confirmed by each center's standard procedure
- LARS score > 30 (major LARS)
- Not previously treated with TAI (except for enemas)
- Completion of training on TAI irrigation by trained medical/nursing staff
- Use of only the Peristeen® Plus device for TAI
- Written informed consent
Exclusion Criteria:
- Neurological diseases
- Psychiatric disorders
- Refusal to consent to follow-up
- Current or planned pregnancy
- Known allergy to latex
- Presence of contraindications as outlined in the device's Instructions for Use (IFU), such as ischemic colitis, acute inflammatory bowel disease, or acute diverticulitis.
Studieplan
Hvordan er undersøgelsen tilrettelagt?
Design detaljer
- Primært formål: Behandling
- Tildeling: Randomiseret
- Interventionel model: Parallel tildeling
- Maskning: Ingen (Åben etiket)
Våben og indgreb
Deltagergruppe / Arm |
Intervention / Behandling |
|---|---|
|
Eksperimentel: Early TAI-treated group
This arm will start trans-anal irrigation within 3 months after stoma closure
|
The procedure involves the introduction of water into the rectum and colon via the anus, which stimulates colonic reflex activity and acts as a mechanical bowel washout, thereby facilitating faecal evacuation.
The device will deliver a controlled amount of warm water using a catheter - cone or balloon catheter - while sitting on the toilet.
Once the desired amount of water has been introduced, the patient will expel the water and bowel contents.
The procedure will take approximately 15-30 minutes, depending on the individual patient's response.
|
|
Andet: Late TAI-treated group
This arm will begin trans-anal irrigation between three and six months after stoma closure
|
The procedure involves the introduction of water into the rectum and colon via the anus, which stimulates colonic reflex activity and acts as a mechanical bowel washout, thereby facilitating faecal evacuation.
The device will deliver a controlled amount of warm water using a catheter - cone or balloon catheter - while sitting on the toilet.
Once the desired amount of water has been introduced, the patient will expel the water and bowel contents.
The procedure will take approximately 15-30 minutes, depending on the individual patient's response.
|
Hvad måler undersøgelsen?
Primære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
Compare the effectiveness of two treatment regimens, initiated within different time frames following ostomy closure, in reducing the number of bowel movements in 24 hours.
Tidsramme: From baseline to 3 months
|
The difference in the change from baseline (V0) in the number of bowel movements (i.e.
defecations) in 24 hours at 3 months after stoma closure (V2) between the early TAI group and the late TAI-treated group.
|
From baseline to 3 months
|
Sekundære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
Efficacy of early administration of TAI in reducing the symptoms of LARS in the longterm period (up to 9 months).
Tidsramme: From baseline to 9 months
|
The difference in the change from baseline (V0) in the number of bowel movements in 24 hours at 6 and 9 months (V3 and V4) after stoma closure between the early TAI group and the late TAI-treated group.
|
From baseline to 9 months
|
|
Efficacy of early administration of TAI in prevent LARS chronicity (prevent the increase of specific symptoms of LARS at all time points).
Tidsramme: From baseline to 9 months
|
The difference in the change from baseline (V0) in the Low Anterior Resection Syndrome (LARS) score (with a focus on the individual components of fecal urgency, incontinence, and incomplete evacuation) at various time points (V2, V3, V4) between the two groups (early TAI and late TAI-treated group).
The LARS score ranges from 0 to 42 points.
Patients are classified into one of three categories: no LARS (0-20 points), minor LARS (21-29 points) or major LARS (30-42 points).
|
From baseline to 9 months
|
|
Efficacy of early administration of TAI improving quality of life at all time points
Tidsramme: From baseline to 9 months
|
Changes in quality of life (QoL) scores (across all domains of the Short Form-36 (SF-36) questionnaire) from baseline (V0) at all time points (V2, V3 and V4), and an evaluation of differences between the two groups.
SF-36 scores for each domain range from 0 to 100, with higher scores indicating a more favourable health state.
|
From baseline to 9 months
|
|
Efficacy of early administration of TAI improving patient satisfaction at all time points
Tidsramme: From baseline to 9 months
|
Change in patient satisfaction at all time points from baseline (V0) using a visual analogue scale (VAS), and evaluation of the differences between the two groups.
The VAS consists of a 10 cm line with two endpoints representing 0 = completely unsatisfied and 10 = completely satisfied.
|
From baseline to 9 months
|
|
Evaluate how various factors, such as the timing of TAI initiation, type of anastomosis, prior neoadjuvant radio-chemotherapy, and other patient baseline characteristics, influence LARS symptoms
Tidsramme: From baseline to 9 months
|
The variation in Low Anterior Resection Syndrome (LARS) scores in relation to factors such as the time at which TAI was initiated, the type of anastomosis, previous neoadjuvant radio-chemotherapy, and other baseline patient characteristics in the two groups was examined.
The LARS score ranges from 0 to 42 points.
Patients are classified into one of three categories: no LARS (0-20 points), minor LARS (21-29 points) or major LARS (30-42 points).
|
From baseline to 9 months
|
Andre resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
Safety and tolerability
Tidsramme: From baseline to 9 months
|
Evaluation of the frequency and severity of adverse events (AEs), serious adverse events (SAEs), devicerelated adverse events (ADEs) and serious device-related adverse events (SADEs) in the two groups
|
From baseline to 9 months
|
Samarbejdspartnere og efterforskere
Sponsor
Datoer for undersøgelser
Studer store datoer
Studiestart (Anslået)
Primær færdiggørelse (Anslået)
Studieafslutning (Anslået)
Datoer for studieregistrering
Først indsendt
Først indsendt, der opfyldte QC-kriterier
Først opslået (Faktiske)
Opdateringer af undersøgelsesjournaler
Sidste opdatering sendt (Faktiske)
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
Sidst verificeret
Mere information
Begreber relateret til denne undersøgelse
Nøgleord
Yderligere relevante MeSH-vilkår
- Postoperative komplikationer
- Patologiske processer
- Neoplasmer efter sted
- Neoplasmer
- Tegn og symptomer, fordøjelsessystemet
- Tarmsygdomme
- Gastrointestinale neoplasmer
- Neoplasmer i fordøjelsessystemet
- Sygdomme i fordøjelsessystemet
- Gastrointestinale sygdomme
- Kolorektale neoplasmer
- Intestinale neoplasmer
- Endetarmssygdomme
- Tyktarmssygdomme
- Patologiske tilstande, tegn og symptomer
- Tegn og symptomer
- Lavt anterior resektionssyndrom
- Rektale neoplasmer
- Forstoppelse
- Fækal inkontinens
Andre undersøgelses-id-numre
- 703/2025/Sper/AOUFe
Plan for individuelle deltagerdata (IPD)
Planlægger du at dele individuelle deltagerdata (IPD)?
Lægemiddel- og udstyrsoplysninger, undersøgelsesdokumenter
Studerer et amerikansk FDA-reguleret lægemiddelprodukt
Studerer et amerikansk FDA-reguleret enhedsprodukt
Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .
Kliniske forsøg med Low Anterior Resection Syndrome (LARS)
-
Seoul National University HospitalRekrutteringLARS - Low Anterior Resection SyndromeKorea, Republikken
-
Ankara UniversityAarhus University Hospital; Dokuz Eylul University; Lokman Hekim ÜniversitesiAfsluttetLARS - Low Anterior Resection Syndrome
-
Sichuan Cancer Hospital and Research InstituteIkke rekrutterer endnuLARS - Low Anterior Resection Syndrome
-
HEM Pharma Inc.Premier Research Group plcIkke rekrutterer endnuLARS - Low Anterior Resection Syndrome
-
Qufora A/SEVAMEDRekrutteringEndetarmskræft | Gastroenterologi | LARS - Low Anterior Resection SyndromeFrankrig
-
Northern Jiangsu People's HospitalChina-Japan Union Hospital, Jilin UniversityAfsluttet
-
National Taiwan University HospitalTilmelding efter invitationLavt anterior resektionssyndrom | Endetarmskræft | LARS - Low Anterior Resection SyndromeTaiwan
-
Northern Jiangsu People's HospitalRekrutteringKolorektal cancer | Postoperativ Ileus | LARS - Low Anterior Resection SyndromeKina
-
University Hospital, AntwerpRekrutteringRektal Adenocarcinom | Total Mesorektal Excision | LARS - Low Anterior Resection Syndrome | Lav anterior resektion | Rektal resektionBelgien
-
KU LeuvenUniversitaire Ziekenhuizen KU LeuvenRekrutteringEndetarmskræft | LARS - Low Anterior Resection SyndromeBelgien
Kliniske forsøg med Water-based transanal irrigation system
-
Qufora A/SIkke rekrutterer endnuKronisk forstoppelse | Fækal inkontinens
-
Seoul National University HospitalColoplast A/STilmelding efter invitationUfrivillig vandladning | Neurogen tarm | Fækal inkontinens | Neurogen blære | Spina Bifida | Fækal påvirkningKorea, Republikken
-
University of AarhusKarolinska University Hospital; Coloplast A/S; Central Jutland Regional Hospital og andre samarbejdspartnereAfsluttetForstoppelse | Fækal inkontinens | RygmarvsskadeDanmark
-
Seoul National University HospitalNational Cancer Center, Korea; Seoul National University Bundang Hospital; SMG-SNU Boramae Medical CenterRekrutteringSøvnforstyrrelse | Søvnløshed | Lavt anterior resektionssyndrom | EndetarmskræftKorea, Republikken
-
Coloplast A/SRekrutteringForstoppelse - Funktionel | Fækal inkontinensDanmark, Italien
-
Baltimore Research & Education Foundation, Inc.University of Maryland, College ParkUkendt
-
Biruni UniversityAfsluttetApikal parodontitis | Postoperative smerter | Asymptomatiske infektionerTyrkiet (Türkiye)
-
University Hospital, RouenAfsluttetKirurgi | Intussusception | Rectocele | Sphincter Ani InkontinensFrankrig
-
Memorial Sloan Kettering Cancer CenterAfsluttetProstatakræftForenede Stater
-
Dartmouth-Hitchcock Medical CenterPenn State UniversityTilmelding efter invitationProlaps af bækkenorganerForenede Stater